GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant

被引：31
|
作者：
Nathwani, Amit C. [1 ,2 ,3 ,4 ]
Tuddenham, Edward [5 ]
Chowdary, Pratima [6 ]
McIntosh, Jenny [4 ]
Lee, Doyoung [5 ]
Rosales, Cecilia [5 ]
Phillips, Mark [7 ]
Pie, Jun [8 ]
Zhou Junfang [9 ]
Meagher, Michael M. [10 ]
Reiss, Ulrike [11 ]
Davidoff, Andrew M. [12 ]
Morton, Chris L. [9 ]
Riddell, Anne [2 ,3 ]
机构：
[1] Freeline, Stevenage, Herts, England
[2] Royal Free NHS Fdn Trust, Katharine Dormandy Haemophilia Ctr, London, England
[3] Royal Free NHS Fdn Trust, Thrombosis Unit, London, England
[4] UCL, Canc Inst, Dept Haematol, London, England
[5] UCL Canc Inst, Dept Haematol, London, England
[6] Royal Free Hosp, KD Haemophilia & Thrombosis Ctr, London, England
[7] UCL, UCL Canc Inst, London, England
[8] KD Haemophilia & Thrombosis Ctr, London, England
[9] St Jude Childrens Res Hosp, Dept Surg, 332 N Lauderdale St, Memphis, TN 38105 USA
[10] St Jude Childrens Res Hosp, Childrens GMP LLC, 332 N Lauderdale St, Memphis, TN 38105 USA
[11] St Jude Childrens Rsch Hosp, Dept Surg, Memphis, TN USA
[12] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-118256
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
489
引用
收藏
页数：3
相关论文
共 50 条
  • [31] MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
    Hong, David S.
    Kang, Yoon-Koo
    Brenner, Andrew Jacob
    Sachdev, Jasgit C.
    Ejadi, Samuel
    Borad, Mitesh J.
    Kim, Tae-You
    Lim, Ho Yeong
    Park, Keunchil
    Becerra, Carlos
    Bader, Andreas G.
    Stoudemire, Jay
    Smith, Susan
    Kim, Sinil
    Beg, Muhammad Shaalan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor:: Results of a phase I study
    Bloch, J
    Bachoud-Lévi, AC
    Déglon, N
    Lefaucheur, JP
    Winkel, L
    Palfi, S
    Nguyen, JP
    Bourdet, C
    Gaura, V
    Remy, P
    Brugières, P
    Boisse, MF
    Baudic, S
    Cesaro, P
    Hantraye, P
    Aebischer, P
    Peschanski, M
    HUMAN GENE THERAPY, 2004, 15 (10) : 968 - 975
  • [33] A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS: FINAL RESULTS
    Phatak, P.
    Brissot, P.
    Wurster, M.
    Adams, P. C.
    Bonkovsky, H. L.
    Gross, J.
    Malfertheiner, P.
    McLaren, G. D.
    Niederau, C.
    Piperno, A.
    Powell, L. W.
    Russo, M.
    Stoelzel, U.
    Stremmel, W.
    Griffel, L.
    Lynch, N.
    Zhang, Y.
    Pietrangelo, A.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S81 - S81
  • [34] AAV8-hLCA5 Subretinal Delivery to the Macula in LCA5-associated Leber Congenital Amaurosis (LCA5-LCA): Preliminary Safety and Efficacy Results of an Ongoing Phase I/II Gene Therapy Trial
    Aleman, Tomas S.
    Cideciyan, Artur V.
    Weber, Mariejel L.
    Santos, Arlene
    Uyhazi, Katherine E.
    Parchinski, Kelsey
    Chung, William
    Margaritis, Paris
    Sun, Junwei
    Scoles, Drew
    Garafalo, Alexandra V.
    Jayagopal, Ashwath
    Yerxa, Benjamin R.
    Tuller, Sarah
    Maguire, Albert
    Bennett, Jean
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [35] Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.
    Bono, Petri
    Virtakoivu, Reetta
    Vaura, Felix
    Jaakkola, Panu
    Shetty, Shishir
    Thibault, Alain
    de Jonge, Maja J. A.
    Minchom, Anna Rachel
    Ma, Yuk Ting
    Yap, Christina
    Robbrecht, Debbie
    Pasanen, Annika
    Skytta, Tanja
    Cruz, Romillie
    Jalkanen, Markku
    Jalkanen, Sirpa
    Mandelin, Jami
    Karvonen, Matti
    Koivunen, Jussi
    Hollmen, Maija
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Phase I/II Prospective Dose Escalation Trial with Proton Based Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base and Cervical Spine: Long-Term Results from Proton Radiation Oncology Group 85-26
    Ioakeim-Ioannidou, M.
    Yeap, B. Y.
    Soetan, Z.
    Packard, D.
    Tejada, A.
    Hegazy, R.
    Todary, E. S. R.
    Adams, J. A.
    Kooy, H. M.
    Giap, F.
    Chen, Y. L.
    DeLaney, T. F.
    Goitein, M.
    Munzenrider, J. E.
    Hug, E. B.
    MacDonald, S. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S118 - S119
  • [37] A phase I/II dose escalating study of daunorubicin combined with imatinib mesylate and cytarabine as induction therapy for chronic myelogenous leukaemia in myeloid blast crisis. Preliminary results of the AFR01 trial.
    Rousselot, P
    Legros, L
    Guilhot, J
    Michallet, M
    Mahon, FX
    Pautas, C
    Guyotat, D
    Guerci, A
    Berthou, C
    Rio, B
    Roy, L
    Berthaud, P
    Guilhot, F
    BLOOD, 2004, 104 (11) : 286A - 287A
  • [38] Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
    Powderly, John D.
    Jang, Sekwon
    Lohr, Joanna
    Spira, Alexander, I
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
    Yang, Jin-Ji
    Pavlakis, Nick
    Xie, Fan
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Preliminary results of an escalating dose phase I/II clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy
    Brade, A.
    Smith, C.
    Sherman, I.
    Bebb, G.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S57 - S58
12345